Business
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
TOKYO, December 11, 2025--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO fo
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2445,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/66bf960f50ccceab917612e55210e7b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wSeEJcBGbFjAvSZZTe_uFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/66bf960f50ccceab917612e55210e7b6","width":960,"height":203},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FEj_KlAa.M7H0qgJREzcjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/66bf960f50ccceab917612e55210e7b6","width":1200,"height":254}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026","length":112,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announcement Follows Year of Dual CEO / COO Model and Returns Company to Single Leader Structure","length":96,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":208,"olType":false},{"type":"text","content":"TOKYO, December 11, 2025--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman.","length":586,"tagName":"p"},{"type":"text","content":"In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick to gain greater insights and understanding of the Japanese company, as the first non-Japanese CEO in the company’s long history.","length":375,"tagName":"p"},{"type":"text","content":"By reverting to the single leader model under Mullick in 2026, Kyowa Kirin aims to establish a more...